Eravacycline is a novel antibiotic of the tetracycline class. One clinical trial indicated that it is at least as effective as ertapenem in treating complicated intra-abdominal infections (cIAIs). Eravacycline may have a role in the treatment of complicated appendicitis. The Food and Drug Administration (FDA) and the European Medicines Agency have approved eravacycline (Xerava, Tetraphase Pharmaceuticals) for the treatment of cIAIs in adults.
Meropenem/vaborbactam is a carbapenem beta-lactamase inhibitor combination that has demonstrated higher clinical cure rates, versus best available therapy, for the treatment of carbapenem-resistant Enterobacteriaceae, among other infections. The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended granting authorisation for meropenem/vaborbactam for the treatment of several types of infection, including cIAIs. Meropenem/vaborbactam is approved by the FDA for the treatment of complicated urinary tract infections in adults.
Imipenem/cilastatin/relebactam is a three-drug combination containing imipenem-cilastatin, a previously FDA-approved antibiotic, and relebactam, a new beta-lactamase inhibitor. The FDA has approved this combination to treat adults with complicated urinary tract infections and cIAIs.
Use of this content is subject to our disclaimer